HOSPITALIZATION FOR PERTUSSIS – A TEN YEARS CASUISTIC FROM A LEVEL III HOSPITAL

Authors

  • Inês Ferreira Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto
  • Diana Pinto Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto
  • Vasco Lavrador Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto
  • Alexandre Fernandes Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto
  • Maria Guilhermina Reis Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto
  • Margarida Guedes Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto
  • Laura Marques Department of Pediatrics of Centro Materno Infantil do Norte, Centro Hospitalar do Porto

DOI:

https://doi.org/10.25753/BirthGrowthMJ.v25.i4.10797

Keywords:

Bordetella pertussis, children, hospital, whooping cough, vaccination

Abstract

Background: Whooping cough remains a concern in pediatric age. Adolescents and adults are recognized as a source of disease transmission, particularly for infants without complete primary immunization. The objectives of this study were to characterize clinically and epidemiologicaly hospitalized pediatric cases of pertussis.

Material and methods: Retrospective, observational study of pediatric patients hospitalized at a level III Portuguese hospital with Bordetella pertussis infection confirmed by PCR DNA assay, between January 2005 and December 2014.

Results: Forty-three patients were admitted with an median duration of eight days. We observed a higher number of admissions in 2008 and 2012, with majority of cases in the summer. The median age was 2,5 months old (minimum 12 days; maximum 16 years), of which 86.0% (n=37) infants without complete primary vaccination. All patients had cough and 48.8% (n=21) had an identified epidemiological contact of pertussis. All were treated with macrolides, with a mean interval between onset of symptoms and treatment of eight days (minimum 2; maximum 60 days). Viral coinfection occurred in 21.6% (n=14). Ten patients were admitted to intensive care unit and two deceased.

Conclusions: Like other studies, there was a incidence peak in 2012. Infants were the most vulnerable age group to infection by Bordetella pertussis, with the highest number of hospitalizations. There is a need for additional prevention strategies to improve prevention in this age group.

Downloads

Download data is not yet available.

References

Munoz FM, Keitel WA. Progress in the diagnosis, prevention and treatment of pertussis. Curr Infect Dis Rep 2003; 5:213-21.

Long SS. Pertussis (Bordetella pertussis and Bordetella parapertussis). In: Kliegman RM, Stanton BF, St Geme III JW, Schor NF, Behrman RE. Nelson Textbook of Pediatrics. Philadelphia: W B Saunders, 2016; 1377-81.

Correia P, Tavares M. Linhas de orientação para o diagnóstico e terapêutica de tosse convulsa. 2010. (Acedido em Dezembro de 2015). Disponível em: http://www.spp.pt/UserFiles/file/Protocolos_SPP/Tosse_Convulsa_2010.pdf

Fisher D, Snyder J. Pertussis in childhood. Pediatr Rev 2012; 33:412-21.

WHO Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. Wkly Epidemiol Rec 2007; 87: 190-5.

CDC Especiales. Tos ferina: lo que debe saber. Outubro, 2015. (Acedido em Dezembro de 2015). Disponível em: http://www.cdc.gov/pertussis/

Cornia P, Lipsky B, Calderhood S, Kaplan S, Baron E. Bordetella pertussis infection: Epidemiology, microbiology and pathogenesis of Bordetella pertussis infection. Outubro, 2015. (Acedido em Dezembro de 2015). Disponível em: http://www.uptodate.com/contents/bordetella-pertussis-infection-epidemiology-microbiology-and-pathogenesis

D’elia C, Casimiro A, Mendes P. Novas estratégias de prevenção da tosse convulsa. Acta Med Port 2011; 42:164-71.

Zepp F et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11:557-70.

Santos MA, Pereira B, Furtado C. Tosse convulsa em Portugal: análise retrospetiva de casos clínicos suspeitos de infeção por Bordetella pertussis no período 2010-2014. Boletim epidemiológico 2015; 4:12-6.

DSP – ARSN, I.P. Caracterização dos casos de tosse convulsa ocorridos na região Norte entre 2004 e 2006. Departamento de Saúde Publica – Administração Regional de Saúde do Norte I.P. Abril, 2008. (Acedido em Dezembro de 2015). Disponível em: http://portal.arsnorte.minsaude.pt/portal/page/portal/ARSNorte/Conte%C3%BAdos/Sa%C3%BAde%20P%C3%BAblica%20Conteudos/DDO_Pertussis_Relatorio0406.pdf

Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Resp Rev 2008; 9: 201-12.

Bamberger E, Srugo I. What is new in pertussis. Eur J Pediatr 2008; 167: 133-9.

Grenha J, Maia C, Fonseca J, Moreira D, João A. Estudo clínico-epidemiológico da infeção por Bordetella pertussis num hospital português de nível III. Acta Pediatr Port 2014; 45:176-82.

Klein NP, Barlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in childen. N Engl J Med 2012; 367:1012-9.

Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis 2009; 49:1565-69.

Grant C, Roberts S, Scragg R, Stewart J, Lennon D, Kivell D, et al. Delayed immunization and risk of pertussis in infants; unmatched case-control study. BMJ 2003; 326:852-3.

Kolos V, Menzies R, McIntyre P. Higher pertussis hospitalization rates in indigenous Australian infants and delayed vaccionation. Vaccine 2007; 25:588-90.

Wandelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24: 58-61.

Cherry JD. The epidemiology of pertussis: A comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115:1422-7.

Blangiardi F, Ferrera G. Reducing the risk of pertussis in newborn infants. J Prev Med Hyg 2009; 50: 206-16.

EUVAC-NET. EUVAC-NET pertussis surveillance report 2003–2007. 2009. (Acedido em Dezembro de 2015). Disponível em: http://ghdx.healthdata.org/record/euvac-net-pertussis-surveillance-report-2003-2007

CDC. Summary of Notifiable Diseases—United States, 2007. MMWR Morb Mortal Wkly Rep 2009; 56:1–94.

Namachivayam P, Shimizu K, Butt W. Pertussis: Severe clinical presentation in pediatric intensive care and its relation to outcome. Pediatr Crit Care Med 2007;8:207-11

Nuolivirta K, Koponen P, He Q, Halkosalo A, Korppi M, Vesikari T, et al. Bordetella pertussis Infection Is Common in Nonvaccinated Infants Admitted for Bronchiolitis. Pediatr Infect Dis J 2010; 29:1-3.

Cherry JD. Comparison of the epidemiology of the disease pertussis vs. the epidemiology Bordetella pertussis infection. Pediatr Res 2003; 53:324A.

Published

2017-02-03

How to Cite

1.
Ferreira I, Pinto D, Lavrador V, Fernandes A, Reis MG, Guedes M, Marques L. HOSPITALIZATION FOR PERTUSSIS – A TEN YEARS CASUISTIC FROM A LEVEL III HOSPITAL. REVNEC [Internet]. 2017Feb.3 [cited 2024Aug.18];25(4):205-10. Available from: https://revistas.rcaap.pt/nascercrescer/article/view/10797

Issue

Section

Original Articles

Most read articles by the same author(s)

<< < 1 2 3 4